Form 4: Teladoc Health Chief Legal Officer Reports Routine Equity Transactions and Tax-Related Stock Sale

Teladoc Health's Chief Legal Officer, Adam C. Vandervoort, reported the acquisition of 11,273 shares of common stock through the vesting of performance and restricted stock units, alongside the sale of 5,808 shares to cover tax obligations.

Summary

• Adam C. Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, Inc. (TDOC), reported recent equity transactions on a Form 4 filing.
• On May 30, 2025, Mr. Vandervoort acquired a total of 11,273 shares of Teladoc Health common stock through the conversion of performance stock units (PSUs) and restricted stock units (RSUs). This included 1,505 shares from PSUs, 4,418 shares from one RSU grant, and 5,350 shares from another RSU grant.
• Following these acquisitions, his direct beneficial ownership of common stock increased to 75,581 shares.
• On June 2, 2025, Mr. Vandervoort sold 5,808 shares of Teladoc Health common stock at a price of $6.86 per share.
• This sale was explicitly stated to cover tax withholding obligations related to the vesting of his performance stock unit and restricted stock unit awards.
• After all reported transactions, Mr. Vandervoort's direct beneficial ownership stands at 69,773 shares of Teladoc Health common stock.
• He also holds remaining derivative securities, including 4,520 Performance Stock Units and 50,704 Restricted Stock Units (13,254 + 37,450).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there was a sale of shares, it was explicitly for tax withholding purposes, which is a routine and expected event. The underlying event is the vesting of a significant number of equity awards, indicating continued executive alignment and participation in the company's equity, which is a positive signal.

Positives

• The vesting of 11,273 performance and restricted stock units indicates continued equity participation and alignment of interests between the executive and shareholders.
• The acquisition of shares through vesting demonstrates the company's commitment to its equity compensation plans for key executives.

Negatives

• The sale of 5,808 shares, while for tax purposes, represents a reduction in the executive's direct common stock holdings.

Future Outlook

NA

Industry Context

This Form 4 filing reflects a routine insider transaction related to executive compensation. Such transactions are common across industries as executives receive equity awards that vest over time, often leading to sales to cover tax liabilities. It does not provide specific insights into broader industry trends in telehealth or healthcare technology.

Comparison to Industry Standards

• The structure of equity compensation (PSUs and RSUs) with vesting schedules and tax-related sales is a standard practice for executive compensation across publicly traded companies, including those in the healthcare technology sector like Amwell (AMWL) or Livongo (LVGO, now part of Teladoc).
• The sale to cover tax withholding is a common and expected event when equity awards vest, aligning with typical executive compensation practices.

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes is a routine event and generally has minimal direct impact on share price or company valuation, unless the volume is unusually large or signals a lack of confidence. The vesting of equity awards aligns executive interests with shareholders.

Key Dates

Keywords

Teladoc Health, TDOC, Adam C. Vandervoort, Chief Legal Officer, Secretary, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Performance Stock Units, Equity Compensation, Executive Compensation, Tax Withholding